X0306 4 2018-05-07 0 0000831547 SPECTRUM PHARMACEUTICALS INC SPPI 0001193918 SHROTRIYA RAJESH C MD 11500 S. EASTERN AVE. SUITE 240 HENDERSON NV 89052 1 0 0 0 Common Stock, $0.001 par value 2018-05-07 4 S 0 30000 15.98 D 759977 I By CS Family Trust Common Stock, $0.001 par value 2018-05-08 4 S 0 30000 16.11 D 729977 I By CS Family Trust Common Stock, $0.001 par value 2018-05-09 4 S 0 30000 16.21 D 699977 I By CS Family Trust Common Stock, $0.001 par value 1787542 I By Shrotriya Gift Trust Common Stock, $0.001 par value 1243284 I By RS Irrevocable Trust Common Stock, $0.001 par value 28907 I By 401(k) Plan Common Stock, $0.001 par value 9523 I By Spouse Common Stock, $0.001 par value 67144 I By Shrotriya Family Foundation Common Stock, $0.001 par value 200652 D All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 19, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.61 to $16.39, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.99 to $16.20, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.09 to $16.30, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Kurt A. Gustafson, attorney-in-fact for Rajesh C. Shrotriya 2018-05-09